Pfizer secures deals to delay generic competition

What’s happening

Pfizer secured agreements to keep a key heart drug protected from generic competition until 2031.

What’s changing / Business impact

• Extends revenue lifecycle of blockbuster drug.
• Delays entry of: lower-cost generics.
• Strengthens pricing power in the short term.

Why this matters

This shows:

• Companies actively manage exclusivity windows.
• Market competition is shaped by legal strategy, not just innovation.
• Drug affordability and access are tied to patent dynamics.